Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
3.000
+0.090 (3.09%)
At close: Jul 26, 2024, 4:00 PM
2.898
-0.102 (-3.40%)
After-hours: Jul 26, 2024, 6:58 PM EDT
Allogene Therapeutics Revenue
Allogene Therapeutics had revenue of $22.00K in the quarter ending March 31, 2024, a decrease of -26.67%. This brings the company's revenue in the last twelve months to $87.00K, down -30.40% year-over-year. In the year 2023, Allogene Therapeutics had annual revenue of $95.00K, down -39.10%.
Revenue (ttm)
$87.00K
Revenue Growth
-30.40%
P/S Ratio
9,376.65
Revenue / Employee
$279
Employees
233
Market Cap
626.35M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 2.00B |
Emergent BioSolutions | 1.19B |
Arcturus Therapeutics Holdings | 124.53M |
Alector | 96.41M |
Verve Therapeutics | 16.05M |
Fate Therapeutics | 6.48M |
ALLO News
- 25 days ago - Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL) - GlobeNewsWire
- 5 weeks ago - Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Announces Q2 Investor Conference Participation - GlobeNewsWire